These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1155 related items for PubMed ID: 23385399

  • 1. Evaluation of feasibility and image quality of 68Ga-DOTATOC positron emission tomography/magnetic resonance in comparison with positron emission tomography/computed tomography in patients with neuroendocrine tumors.
    Gaertner FC, Beer AJ, Souvatzoglou M, Eiber M, Fürst S, Ziegler SI, Brohl F, Schwaiger M, Scheidhauer K.
    Invest Radiol; 2013 May; 48(5):263-72. PubMed ID: 23385399
    [Abstract] [Full Text] [Related]

  • 2. Integrated whole-body PET/MR hybrid imaging: clinical experience.
    Quick HH, von Gall C, Zeilinger M, Wiesmüller M, Braun H, Ziegler S, Kuwert T, Uder M, Dörfler A, Kalender WA, Lell M.
    Invest Radiol; 2013 May; 48(5):280-9. PubMed ID: 23442775
    [Abstract] [Full Text] [Related]

  • 3. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results.
    Beiderwellen KJ, Poeppel TD, Hartung-Knemeyer V, Buchbender C, Kuehl H, Bockisch A, Lauenstein TC.
    Invest Radiol; 2013 May; 48(5):273-9. PubMed ID: 23493121
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Impact of Multiphase 68Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors.
    Ruf J, Heuck F, Schiefer J, Denecke T, Elgeti F, Pascher A, Pavel M, Stelter L, Kropf S, Wiedenmann B, Amthauer H.
    Neuroendocrinology; 2010 May; 91(1):101-9. PubMed ID: 19996582
    [Abstract] [Full Text] [Related]

  • 6. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.
    Putzer D, Gabriel M, Henninger B, Kendler D, Uprimny C, Dobrozemsky G, Decristoforo C, Bale RJ, Jaschke W, Virgolini IJ.
    J Nucl Med; 2009 Aug; 50(8):1214-21. PubMed ID: 19617343
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Detection of pancreatic neuroendocrine tumors (PNET) using semi-quantitative [68Ga]DOTATOC PET in combination with multiphase contrast-enhanced CT.
    Froeling V, Röttgen R, Collettini F, Rothe J, Hamm B, Brenner W, Schreiter N.
    Q J Nucl Med Mol Imaging; 2014 Sep; 58(3):310-8. PubMed ID: 25265251
    [Abstract] [Full Text] [Related]

  • 9. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors.
    Frilling A, Sotiropoulos GC, Radtke A, Malago M, Bockisch A, Kuehl H, Li J, Broelsch CE.
    Ann Surg; 2010 Nov; 252(5):850-6. PubMed ID: 21037441
    [Abstract] [Full Text] [Related]

  • 10. Impact of peptide receptor radionuclide therapy on the 68Ga-DOTATOC-PET/CT uptake in normal tissue.
    Giesel FL, Stefanova M, Schwartz LH, Afshar-Oromieh A, Eisenhut M, Haberkorn U, Kratochwil C.
    Q J Nucl Med Mol Imaging; 2013 Jun; 57(2):171-6. PubMed ID: 23370092
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Radiation exposure of patients during 68Ga-DOTATOC PET/CT examinations].
    Hartmann H, Zöphel K, Freudenberg R, Oehme L, Andreeff M, Wunderlich G, Eisenhofer G, Kotzerke J.
    Nuklearmedizin; 2009 Jun; 48(5):201-7. PubMed ID: 19639164
    [Abstract] [Full Text] [Related]

  • 13. Simultaneous 68Ga-DOTATOC-PET/MRI for IMRT treatment planning for meningioma: first experience.
    Thorwarth D, Henke G, Müller AC, Reimold M, Beyer T, Boss A, Kolb A, Pichler B, Pfannenberg C.
    Int J Radiat Oncol Biol Phys; 2011 Sep 01; 81(1):277-83. PubMed ID: 21300465
    [Abstract] [Full Text] [Related]

  • 14. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions.
    Eiber M, Takei T, Souvatzoglou M, Mayerhoefer ME, Fürst S, Gaertner FC, Loeffelbein DJ, Rummeny EJ, Ziegler SI, Schwaiger M, Beer AJ.
    J Nucl Med; 2014 Feb 01; 55(2):191-7. PubMed ID: 24309383
    [Abstract] [Full Text] [Related]

  • 15. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
    Schmidt H, Brendle C, Schraml C, Martirosian P, Bezrukov I, Hetzel J, Müller M, Sauter A, Claussen CD, Pfannenberg C, Schwenzer NF.
    Invest Radiol; 2013 May 01; 48(5):247-55. PubMed ID: 23519008
    [Abstract] [Full Text] [Related]

  • 16. Simultaneous PET/MR imaging in a human brain PET/MR system in 50 patients--current state of image quality.
    Schwenzer NF, Stegger L, Bisdas S, Schraml C, Kolb A, Boss A, Müller M, Reimold M, Ernemann U, Claussen CD, Pfannenberg C, Schmidt H.
    Eur J Radiol; 2012 Nov 01; 81(11):3472-8. PubMed ID: 22260898
    [Abstract] [Full Text] [Related]

  • 17. Simultaneously acquired MR/PET images compared with sequential MR/PET and PET/CT: alignment quality.
    Brendle CB, Schmidt H, Fleischer S, Braeuning UH, Pfannenberg CA, Schwenzer NF.
    Radiology; 2013 Jul 01; 268(1):190-9. PubMed ID: 23657890
    [Abstract] [Full Text] [Related]

  • 18. 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial.
    Etchebehere EC, de Oliveira Santos A, Gumz B, Vicente A, Hoff PG, Corradi G, Ichiki WA, de Almeida Filho JG, Cantoni S, Camargo EE, Costa FP.
    J Nucl Med; 2014 Oct 01; 55(10):1598-604. PubMed ID: 25168627
    [Abstract] [Full Text] [Related]

  • 19. [Detection of a neuroendocrine differentiated cystic pancreatic lesion by gallium-68-DOTATOC-PET/CT with inconclusive MRI, CT and ultrasound diagnosis].
    Fröling V, Denecke T, Pöllinger A, Schreiter NF.
    Rofo; 2010 Feb 01; 182(2):175-7. PubMed ID: 19998214
    [No Abstract] [Full Text] [Related]

  • 20. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors.
    Kowalski J, Henze M, Schuhmacher J, Mäcke HR, Hofmann M, Haberkorn U.
    Mol Imaging Biol; 2003 Feb 01; 5(1):42-8. PubMed ID: 14499161
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 58.